Butterfly Network, Inc. filings document the formal disclosures of a public digital health company built around Ultrasound-on-Chip devices, ultrasound software and AI. Recent 8-K reports furnish quarterly and annual results, business updates, material agreements, executive and director matters, and listing-status notices affecting securities issued in connection with its prior business combination with Longview Acquisition Corp.
Proxy materials describe annual meeting proposals, director elections, auditor ratification and executive-compensation votes. Other filings cover the company’s Class A common stock, public warrants, capital structure and governance, including the NYSE Form 25 record for removal of the warrants from listing and registration, while operating disclosures address point-of-care ultrasound and Butterfly Embedded licensing activity.
Butterfly Network, Inc. director Larry Robbins reported indirect sales of 2,297,733 shares of Class A Common Stock between August 13 and 17, 2026. The shares were sold in open-market transactions by investment entities Glenview Offshore Opportunity Master Fund, Ltd., Glenview Healthcare Master Fund, L.P., and Longview Investors LLC or its affiliates, with weighted average prices per transaction ranging from about $8.70 to $9.54. Robbins is an investment manager or managing member for these entities, may be deemed to share voting and dispositive power, and disclaims beneficial ownership beyond any pecuniary interest. A separate entry shows 390,952 shares of Class A Common Stock held directly by Robbins as of August 13, 2026.
Butterfly Network, Inc. insider Jonathan M. Rothberg, Ph.D. filed Amendment No. 12 to his Schedule 13D, updating his ownership and trading arrangements in the company’s dual-class common stock. He is reported as beneficially owning 828,775 shares of Class A common stock, representing 0.3% of the Class A shares outstanding as of July 24, 2026, including 80,434 shares held directly, options for 21,645 shares exercisable within 60 days, and 726,696 shares held by his spouse. He is also reported as beneficially owning 21,426,937 shares of Class B common stock, equal to 100% of the Class B shares outstanding, held through 4C Holdings I–V, LLC. The filing discloses a Rule 10b5-1 trading plan for estate-planning purposes, permitting potential sales of up to 363,348 Class A shares and 8,049,929 Class B shares through November 12, 2027, subject to minimum price and volume conditions, with no assurance any sales will occur.
It also reports that on July 22, 2026, 659,913 Class B shares were sold at a weighted average price of $6.4698 per share, and those shares automatically converted into Class A common stock on a one-to-one basis upon sale.
Butterfly Network, Inc. director Louise S. Phanstiel, through The Phanstiel Trust u/a/d 2/5/02, purchased 115,200 shares of Class A Common Stock on 2026-08-14 at a weighted average price of $8.6763 per share, with trade prices ranging from $8.49 to $8.865 per share.
After this transaction, indirect holdings via the trust total 300,461 shares, and a separate entry reports 390,952 shares held directly. The filing does not indicate use of a Rule 10b5-1 trading plan.
Hood River Capital Management LLC reports beneficial ownership of Butterfly Network Inc. common stock. The firm holds 13,190,130 shares, representing 5.61% of the outstanding common stock. Hood River has sole dispositive power over these shares but reports no voting power, either sole or shared.
Butterfly Network, Inc. insider Nicholas Caezza, Deputy General Counsel, reported a sale of 10,000 shares of Class A common stock on 2026-08-11 at $9.75 per share in an open market or private transaction. Following this sale, Caezza directly holds 300,307 shares of Class A common stock. The filing indicates the Rule 10b5-1 trading-plan checkbox was not selected.
Butterfly Network, Inc. director and President & CEO Joseph DeVivo reported selling 68,346 shares of Class A common stock on August 10, 2026 at a weighted average price of $10.009 per share. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2025, and DeVivo reported holding 7,603,700 shares of Class A common stock directly following the transaction.
Butterfly Network, Inc. insider Nicholas M. Caezza filed a notice of proposed sale of 10,000 Class A shares of common stock through Fidelity Brokerage Services LLC. The shares, carrying an aggregate market value of approximately $97,500.00, may be sold on the NYSE beginning on 08/11/2026.
The 10,000 shares were acquired from the issuer as compensation via restricted stock vesting on 03/01/2025. Caezza also reports a prior sale within the past three months of 1,733 Class A shares on 06/02/2026 for total proceeds of $7,831.25.
Butterfly Network, Inc. reported that Dr. Erica Schwartz has resigned from its Board of Directors, effective automatically upon her confirmation as Director of the U.S. Centers for Disease Control and Prevention on August 5, 2026. The company states that her resignation does not result from any disagreement regarding operations, policies, or practices.
A press release dated August 11, 2026, attached as an exhibit, further notes that Dr. Schwartz had served on the Board since 2021 and stepped down in advance of assuming her new role at the CDC. Butterfly Network’s President, CEO and Chairman, Joseph DeVivo, is quoted recognizing her contributions and service to the company.
Butterfly Network insider Joseph M. Devivo filed notice of intent to sell 68,346 Class A shares of common stock, expected from restricted stock vesting on December 17, 2024. The shares are held at Fidelity Brokerage Services and are listed on the NYSE.
Butterfly Network, Inc. insider Dawn Carfora filed to sell common stock under Rule 144 through Merrill Lynch. The planned sale covers 8,770 shares of common stock, with an indicated market value of $85,511.74, on the NYSE. The filing notes that Butterfly Network had 244,858,246 shares outstanding as of this notice. The shares derive from restricted stock unit awards that vested on 02/16/2022 and 02/16/2023, each for 4,385 shares and granted under the issuer’s equity compensation plan. In the past three months, Carfora also sold 176,301 shares of common stock for proceeds of $1,644,606.95 on 06/29/2026.